新四联疗法治疗幽门螺杆菌相关性胃炎疗效分析

Curative effect analysis of new quadruple therapy in the treatment of helicobacter pylori associated gastritis

目的:探究利用三联疗法和荆花胃康胶丸组成的新四联疗法治疗幽门螺杆菌相关性胃炎的疗效。方法:随机将472例相关性胃炎患者分成对照组和观察组,对照组244例患者使用三联疗法联合胶体果胶铋治疗;观察组228例患者使用三联疗法联合荆花胃康胶丸治疗。跟踪观察两组患者的临床症状改善情况和药物不良反应。结果:对照组出现13例不良反应,观察组出现1例不良反应(P<0.01),幽门螺杆菌根除率分别为89.18%(206/231)和85.46%(194/227)。在治疗1周后、8周后,对比两组幽门螺杆菌相关性胃炎患者的临床症状,可见观察组的临床症状得到显著的改善(Uc=2.387/2.413,P<0.05)。结论:新四联疗法在临床症状方面的改善和药物安全性方面比含铋四联疗法的效果显著。

Objective:To explore the curative effect of using new quadruple therapy composed of triple therapy and Jing Hua Wei Kang capsule in the treatment of helicobacter pylori associated gastritis.Methods:472 patients with associated gastritis were randomly divided into the control group and the observation group.244 patients in the control group were treated by triple therapy combined with colloidal bismuth pectin.228 patients in the observation group were treated by triple therapy combined with Jing Hua Wei Kang capsule.The clinical symptoms improvement and adverse drug reactions of patients in two groups were tracking observed.Results:The control group appeared 13 cases of adverse reactions,and the observation group appeared 1 case of adverse reaction(P<0.01).The Helicobacter pylori eradication rates were respectively 89.18%(206/231) and 85.46%(194/227).After 1week and 8 weeks treatment,the clinical symptoms of patients with helicobacter pylori associated gastritis in two groups were compared,the clinical symptom of the observation group were improved significantly(Uc=2.387/2.413,P<0.05).Conclusion:In the clinical symptoms improvement and medication safety,the effect of new quadruple therapy is significant than containing bismuth quadruple therapy.